regardless of promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant resistance from managed care entities. The https://henriuejk128377.thezenweb.com/company-s-vyndamax-faces-is-dealing-with-pbm-obstacles-a-look-at-access-disputes-80816748